Inflation – Talk Bio

Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect

2 weeks ago talkbio0Tagged AstraZeneca, Centers for Medicare & Medicaid Services, drug price, Farxiga, Inflation, Medicare, negotiation, petition, pharmaceutical lawsuits, price controls, SCOTUS, Supreme Court

Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls

Two Courts Reject Challenges to Inflation Reduction Act, Marking Major Win for Government

4 months ago talkbio0Tagged administrative law, AstraZeneca, constitutional challenge, Drug Negotiation Program, federal courts, Inflation, Ira (eukaryote), Medicare, Myasthenic Syndromes, Congenital, Third Circuit Court

Inflation Reduction Act; IRA; Medicare Drug Negotiation Program; AstraZeneca; federal courts; constitutional challenge; administrative law; Third Circuit Court; CMS; Medicare

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

7 months ago talkbio0Tagged concessions, credit card fees, DOJ, False Claims Act, Inflation, lawsuit, Medicare fraud, Prices, Sales - occupational activity

False Claims Act, Medicare fraud, average sales price inflation, credit card fees, price concessions, DOJ lawsuit

Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs

11 months ago talkbio0Tagged drug price, Health care facility, Inflation, Mediation, Medicare, Prescription procedure, seniors, Wegovy

Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.

Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change

11 months ago talkbio0Tagged Administration occupational activities, CMS, drug price, Inflation, Medicare, Myasthenic Syndromes, Congenital, negotiation, Prices, Transplant Registry Unified Management Program

Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process

Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns

1 year ago talkbio0Tagged Acquisitions, Administration occupational activities, Biopharma, Independence, Inflation, mergers, Policy, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vaccines

Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

1 year ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024

Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform

1 year ago talkbio0Tagged 2024, Biopharma, Donald Trump, Drug Industry, Drug Pricing Reform, Inflation, Kamala Harris, Mediation, Medicare, presidential election, Prices

Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.

Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government

1 year ago talkbio0Tagged court, Drug Industry, drug price, federal, Government, Inflation, Ira (eukaryote), lawsuit, Medicare, Negotiation Program, Novartis, victory

Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory